STOCK TITAN

Inozyme Pharma, Inc. - INZY STOCK NEWS

Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at treating rare metabolic diseases. Focusing on disorders linked to paradoxical mineralization, Inozyme is pioneering solutions for conditions impacting vasculature, soft tissue, and skeletal health. Their lead drug, INZ-701, is an enzyme replacement therapy designed to correct defects in pathways involving ENPP1 and ABCC6 deficiencies.

INZ-701 showcases promise in treating diseases such as pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI). This drug, currently in Phase 1/2 clinical trials, has demonstrated positive preliminary results, including safety, pharmacokinetic, and pharmacodynamic data, as well as trends toward clinical improvement. The trials indicate that INZ-701 increases plasma pyrophosphate (PPi) levels, a crucial marker for these conditions.

During the trials, INZ-701 was generally well tolerated with favorable safety profiles. Inozyme has undertaken comprehensive natural history studies to better understand the progression of ABCC6 Deficiency, especially in pediatric populations at high risk for severe complications like strokes.

In addition to their clinical advancements, Inozyme is committed to expanding its pipeline and therapeutic focus, planning pivotal trials for both pediatric and adult populations affected by these genetic disorders. The company also actively engages with patient communities and global health institutions to further research and raise awareness.

For real-time updates and detailed information, visit Inozyme Pharma or follow them on LinkedIn, X (formerly Twitter), and Facebook.

Rhea-AI Summary

Inozyme Pharma announced that the FDA has granted Fast Track designation to INZ-701 for treating ABCC6 Deficiency, a rare, severe condition affecting children and leading to significant clinical events such as stroke and severe neurological and cardiovascular diseases. The decision is based on nonclinical pharmacology data and preliminary safety and efficacy data from the ongoing Phase 1/2 trial in adults. This designation will facilitate more frequent FDA engagement and expedited regulatory review. Inozyme aims to finalize plans for a pivotal pediatric study by the end of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
-
Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company, will present findings from a radiographic study on pediatric patients with ENPP1 Deficiency at the 11th International Conference on Children’s Bone Health (ICCBH) in Salzburg, Austria, from June 22-25, 2024.

The presentation titled, 'Expanding the spectrum of radiographic features in children with ENPP1 Deficiency: Novel skeletal findings from an international collaboration,' will be delivered by Dr. Leanne Ward on June 24, 2024, between 11:00-12:00 CEST. Additionally, Inozyme will sponsor a symposium on June 22, 2024, from 13:45-14:45 CEST, focusing on ENPP1 Deficiency as an overlooked cause of hypophosphatemic rickets, chaired by Dr. Agnes Linglart and featuring presentations by Dr. Zulf Mughal and Dr. David Weber.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company specializing in rare diseases, announced that its CEO and Chairman, Doug Treco, Ph.D., will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 6, 2024, from 12:30 to 12:55 pm ET. A live webcast will be available on the Investor Relations section of Inozyme's website, with a replay accessible for a time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
conferences
Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS) 2024 in Marseille, France, from May 25-28, and at the Endocrine Society's Annual Meeting (ENDO) 2024 in Boston, Massachusetts, from June 1-4. Key topics include the impact of INZ-701 on bone and mineral metabolism biomarkers and clinical outcomes in adults with ENPP1 Deficiency, as well as the safety and exploratory efficacy of INZ-701 in adults with ABCC6 Deficiency manifesting as pseudoxanthoma elasticum (PXE).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences clinical trial
-
Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY) will participate in the Bank of America Securities 2024 Health Care Conference with CEO Doug Treco. The company focuses on developing therapeutics for rare diseases related to mineralization and intimal proliferation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
conferences
-
Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY) reported positive interim data from Phase 1 trials of INZ-701 in end-stage kidney disease and ENPP1 Deficiency. Cash on hand expected to fund operations into Q4 2025. The company aims to address unmet needs in ABCC6 Deficiency and calciphylaxis. Financially, cash, cash equivalents, and short-term investments were $166.2 million, with R&D expenses at $19.1 million and net loss of $23.3 million for Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.74%
Tags
Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY) granted stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of up to 20,000 shares at $4.61 per share, vesting over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) announces positive safety and efficacy data for INZ-701 in ABCC6 and ENPP1 Deficiency. The company shows promising results in vascular pathology, visual function, and patient-reported outcomes. The press release highlights the potential benefits of INZ-701 in treating genetic diseases. Notable improvements were observed in clinical markers, including carotid intima-media thickness, choroidal thickness, visual function, and global impression of change. The company plans to initiate a pivotal trial for pediatric ABCC6 Deficiency in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.42%
Tags
-
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) granted stock options to three new employees under its 2023 Inducement Stock Incentive Plan. The options allow the purchase of up to 80,000 shares at an exercise price of $6.93 per share. The options have a 10-year term and vest over four years, with 25% of shares vesting on the first anniversary and monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.42%
Tags
none
Rhea-AI Summary
Inozyme Pharma, Inc. (INZY) announces CEO's participation in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on developing therapeutics for rare diseases. The event will be live webcasted and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
conferences

FAQ

What does Inozyme Pharma specialize in?

Inozyme Pharma specializes in the development of novel therapeutics aimed at treating rare metabolic diseases, focusing on disorders of paradoxical mineralization.

What is INZ-701?

INZ-701 is an enzyme replacement therapy developed by Inozyme Pharma to correct defects in pathways involving ENPP1 and ABCC6 deficiencies. It is currently in Phase 1/2 clinical trials.

What conditions is INZ-701 intended to treat?

INZ-701 is intended to treat rare genetic diseases such as ENPP1 Deficiency and ABCC6 Deficiency, which include conditions like pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI).

What are the latest clinical trial results for INZ-701?

Recent trials have shown that INZ-701 is generally safe and well-tolerated, increasing PPi levels in patients, with trends toward clinical improvement observed.

What are ENPP1 and ABCC6 Deficiencies?

ENPP1 and ABCC6 Deficiencies are rare genetic conditions that affect the body's mineralization processes, leading to severe health issues such as vascular calcification, rickets, osteomalacia, and cardiovascular complications.

Does Inozyme Pharma have any ongoing clinical trials?

Yes, Inozyme is conducting Phase 1/2 clinical trials for INZ-701 in adult patients with ENPP1 Deficiency and ABCC6 Deficiency.

What is the significance of plasma pyrophosphate (PPi) levels?

Plasma pyrophosphate (PPi) levels are a crucial marker in the treatment of ENPP1 and ABCC6 Deficiencies. Increased PPi levels indicate potential clinical benefits of INZ-701.

What partnerships does Inozyme Pharma have?

Inozyme collaborates with patient communities, healthcare professionals, and global health institutions to advance research and develop treatments for rare metabolic diseases.

How can I stay updated on Inozyme Pharma's progress?

You can stay updated by visiting Inozyme Pharma's website or following them on LinkedIn, X (formerly Twitter), and Facebook.

What are Inozyme Pharma's future plans?

Inozyme plans to advance INZ-701 through pivotal trials in pediatric patients and expand its therapeutic focus to address various rare genetic disorders affecting mineralization processes.

Inozyme Pharma, Inc.

Nasdaq:INZY

INZY Rankings

INZY Stock Data

329.69M
61.86M
0.52%
92.74%
4.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON